Perception versus reality: A National Cohort Analysis of the surgery ‐first approach for resectable pancreatic cancer

ConclusionDespite the perceived benefit of UFS, only 1-in-5 UFS patients actually realize maximal survival when known factors highly associated with outcomes are assessed. Patients are proportionally more likely to do worst, rather than best after UFS treatment. Similarly staged patients undergoing ITT-neoadjuvant therapy achieve survival superior to the majority of UFS patients. Patients and providers should be aware of the false perception of ‘optimal’ survival benefit with UFS in anatomically resectable PDAC.

Source: Cancer Medicine - July 21, 2021 Category: Cancer & Oncology Authors: John R. Bergquist, Cornelius A. Thiels, Christopher R. Shubert, Tommy Ivanics, Elizabeth B. Habermann, Santhi S. Vege, Travis E. Grotz, Sean P. Cleary, Rory L. Smoot, Michael L. Kendrick, David M. Nagorney, Mark J. Truty Tags: RESEARCH ARTICLE Source Type: research